Allergan, Ligand Pharmaceuticals to Take Cancer-Cure Venture Public
- Share via
IRVINE — Allergan Inc. said Tuesday that its venture with Ligand Pharmaceuticals Inc. will go public. Shareholders in the two companies will be offered $32.5 million worth of stock in the joint venture, called Ligand and Allergan Ligand Retinoid Therapeutics Inc.
The research and development venture between San Diego-based Ligand and Allergan, based in Irvine, began in June, 1992, to develop a treatment for cancer.
Investors in the joint venture will be given the option of buying units that consist of two warrants to purchase Ligand stock and one share of common stock in the new company.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
